Charting The Changing Landscape in Multiple Myeloma from Frontline to Relapsed/Refractory Disease
View More
Cases and Conversations™: Nursing Considerations for the Management of ER+ Breast Cancer
View More
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
View More
Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
ACCC 40th National Oncology Conference Pre-Session: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward
Register Now!
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Pembrolizumab Combos Miss Survival End Points in Metastatic NSCLC
Pembrolizumab plus lenvatinib does not improve objective response rate compared with standard-of-care treatment among patients with metastatic non–small cell lung cancer in the phase 3 LEAP-006 and LEAP-008 trials.
Longer Surgery Delay After CRT Does Not Improve Esophageal Cancer Responses
Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.
Ibrutinib Reduces Risk of Next Treatment Initiation Vs CIT in CLL/SLL
Treatment with ibrutinib significantly reduces the risk of initiating next treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared with bendamustine/rituximab in a real-world setting.
Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer
A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.
Elacestrant Earns EU Approval for ESR1+, ER+, HER2– Advanced Breast Cancer
September 22nd 2023The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.
Pembrolizumab Combo Receives FDA Priority Review in Cervical Cancer
Findings from the phase 3 KEYNOTE-A18 trial support the supplemental biologics license application for a pembrolizumab-based regimen as a treatment for patients with newly diagnosed, high-risk, locally advanced cervical cancer.